Organization
Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
3 abstracts
Abstract
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).Org: Clinica São Germano, São Paulo, Brazil, Medical University of Lodz, Lodz, Poland, Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland, The First Affiliated Hospital of Soochow University, Suzhou, China, Gorodskaya Klinicheskaya Bol'nitsa Im. Botkina, Moscow, Russian Federation,
Abstract
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.Org: Dana-Farber Cancer Institute, Bristol Myers Squibb, Institute for Myeloma and Bone Cancer Research, Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Catalan Institute of Oncology and Josep Carreras Institute,
Abstract
Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.Org: Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, University Federico II, Cimitile, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST (IRCCS) s,